Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2016 - 2025)

Lineage Cell Therapeutics' Cash from Financing Activities history spans 16 years, with the latest figure at $20.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 6.23% year-over-year to $20.4 million; the TTM value through Dec 2025 reached $27.0 million, down 24.84%, while the annual FY2025 figure was $27.0 million, 24.84% down from the prior year.
  • Cash from Financing Activities reached $20.4 million in Q4 2025 per LCTX's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $21.7 million in Q4 2024 to a low of -$307000.0 in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $5.4 million, with a median of $959000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 1402000.0% in 2024, then crashed 392.38% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $954000.0 in 2021, then tumbled by 87.21% to $122000.0 in 2022, then crashed by 110.66% to -$13000.0 in 2023, then skyrocketed by 167284.62% to $21.7 million in 2024, then dropped by 6.23% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Cash from Financing Activities are $20.4 million (Q4 2025), $1.8 million (Q3 2025), and -$307000.0 (Q2 2025).